BTIG Raises Caris Life Sciences (CAI) Price Target to $38
Key Points
- BTIG raised its price target on Caris Life Sciences from $33 to $38, maintaining a Buy rating as of October 27, 2026.
- BTIG's $38 price target implies 12.21% upside from Caris Life Sciences, Inc.'s ($CAI) current $33.87 share price.
- The stock recently traded at $33.87, about equal to its closing price on the same day, and is above its 50-day moving average by 20.2%.
- Caris Life Sciences reported trailing twelve-month revenue of approximately $989.6 million, with a net margin of 10.6%.
Get Caris Life Sciences text alerts
We text you when insiders, Congress, analysts or big funds move on $CAI.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Caris Life Sciences, Inc. alert may contain errors. Disclosures
On October 27, 2026, BTIG raised its price target on Caris Life Sciences, Inc. (CAI) to $38 from $33, while maintaining a Buy rating. This update comes as Caris continues to show strong performance in the biotechnology sector, particularly with its innovative molecular profiling services.
BTIG's new target reflects confidence in Caris's growth potential. The firm's action indicates they believe the stock can rise further, as it has recently traded around $33.87, which is about equal to its closing price on the same day. The shares are currently above their 50-day moving average by 20.2% and well above the 200-day moving average by 58.2%.
CAI
Caris Life Sciences, Inc.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Caris Life Sciences
Several other institutional investors have made notable moves in Caris Life Sciences. E. Ohman J:or Asset Management holds 125,000 shares valued at about $3.83 million. Braidwell LP increased its stake by 246,688 shares, bringing its total to 8,256,032 shares worth approximately $279.6 million. Meanwhile, J. H. Whitney Equity Partners VI, LLC reduced its holdings by 6,999,329 shares, now owning 11,256,615 shares valued at about $381.3 million.
Caris Life Sciences, Inc. Stock Up 4.3%
Caris Life Sciences is currently trading at $33.87, near its 52-week high of $33.89. This positioning suggests strong investor interest and confidence in the company's future. The stock is above its 52-week low of $14.19, reflecting a significant recovery and growth over the past year.
$CAI price target
Caris Life Sciences, Inc. daily closes and this analyst's $38 target. Not advice.
Recent Earnings
Caris Life Sciences reported trailing twelve-month revenue of approximately $989.6 million, showcasing a year-over-year revenue growth of 45.4%. The company's net margin stands at 10.6%, and it has a return on equity of 20.1%. The next earnings report is set for November 4, 2026.
Insider Buying and Selling at Caris Life Sciences, Inc.
In recent insider activity, Director Jeff L Vacirca bought 31,050 shares at an average price of $16.15 on May 11, 2026, totaling about $501,426. Other insiders, including President David Baxley and Officer Brian J. Brille, have sold shares, with Brille offloading 400,000 shares at an average price of $30.33 on September 17, 2026, amounting to about $12.13 million.
Analysts Set New Price Targets
On October 27, 2026, BTIG raised its price target on Caris Life Sciences to $38 while maintaining a Buy rating. This follows other recent analyst actions, including TD Cowen maintaining a Buy rating with a target of $36 and JP Morgan holding an Overweight rating with a target of $35. The consensus price target among analysts is approximately $32.08 with 13 opinions.
About Caris Life Sciences
Caris Life Sciences, Inc. is a biotechnology company that provides molecular profiling services. Based in Irving, Texas, the firm aims to transform healthcare through its advanced molecular information and artificial intelligence technology.
Bottom Line
Investors should watch for Caris Life Sciences' upcoming earnings report on November 4, 2026. The recent price target increase by BTIG reflects confidence in the company's growth trajectory, especially following the strong revenue performance reported.
Related Filing Alerts
Source: BTIG's rating change on $CAI (Oct 27, 2026). Written by software, not financial advice. How we make alerts